Saturday, August 18, 2018
 
 
Company News: Page (1) of 1 - 05/17/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
argenx to Present at Upcoming Investor Conferences
By Globenewswire

May 17, 2018

Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present at several upcoming investor conferences:

  • UBS 2018 Global Healthcare ConferenceCompany presentation on Tuesday, May 22, 2018 at 2:00 p.m. ET in New York City.
  • Jefferies 2018 Global Healthcare Conference. Company presentation on Wednesday, June 6, 2018 at 1:30 p.m. ET in New York City.
  • JMP Securities Life Sciences ConferencePanel discussion on Wednesday, June 20, 2018 at 10:30 a.m. ET in New York City.

Live webcasts of the UBS and Jefferies presentations will be available on the Company's website at www.argenx.com. Replays of the webcasts will be available for 90 days following the presentation.

About argenx
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.  



www.argenx.com

For further information, please contact:

Joke Comijn, Corporate Communications & IR Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
[email protected]

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
[email protected]

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should," and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including argenx's expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates; argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.


Page: 1


 





About Video Based Tutorials - Contact Us - Advertise With Us - Privacy Guidelines